France Diabetes Drugs and Devices Market Introduction and Overview
According to SPER Market Research, the France Diabetes Drugs and Devices Market is estimated to reach USD 1.99 billion by 2033 with a CAGR 2.63%.
The report includes an in-depth analysis of the France Diabetes Drugs and Devices Market, including market size and trends, product mix, distribution channels, and supplier analysis. Diabetic pharmaceuticals are medications designed to stabilise and manage blood glucose levels in patients with diabetes. Diabetic medications have been proposed as prospective treatment options for diabetic people infected with SARS-CoV-2. Diabetes mellitus type 1 and type 2 can be treated with diabetes medications that lower blood glucose levels. Type 2 diabetes, also known as non-insulin-dependent diabetes or adult-onset diabetes, is a condition in which the body does not use insulin efficiently. Type 2 diabetes is most commonly caused by obesity and a lack of exercise. The substantial increase in the number of type 2 diabetes is mostly due to the country's rising obesity rates and unhealthy lifestyles characterised by poor eating habits and insufficient physical activity.
- November 2023: Novo Nordisk announced an investment of more than 16 billion Danish kroner (2.26 billion USD) beginning in 2023 to expand the existing production site in Chartres, France, for the current and future product portfolio in serious chronic diseases including diabetes. The investment will greatly improve the manufacturing site's capacity by adding aseptic and completed production processes, as well as extending the current Quality Control Laboratory.
- November 2023: ViCentra, Diabeloop, and Dexcom will launch a closed-loop diabetes system in Europe in 2024 to assist persons with Type 1 diabetes in better managing their disease.
Market Opportunities and Challenges
Opportunities: The increasing usage of insulin-delivery devices, as well as the rising prevalence of diabetes, are driving market expansion. A sedentary lifestyle and bad habits are contributing to an increased incidence of Type-2 diabetes diagnoses. According to the International Diabetes Federation (IDF), around 537 million persons are diabetic. This can cause the development of a variety of chronic diseases in the human body. As a result, managing and controlling diabetes is critical. Furthermore, patients around the world are becoming more aware of their conditions and seeking treatment in hospitals and clinics. A shift in knowledge and the drive to treat diabetes are driving up global demand for diabetic care equipment. Diabetes is increasingly common in middle and lower-middle-class households; thus the market will find profitable potential in emerging economies with good reimbursement rates.
Challenges:
High Initial expenditure: The high initial expenditure necessary for developing and implementing Diabetes Care Devices & Drugs solutions, particularly for large-scale initiatives, can be a substantial impediment to market growth.
Market Fragmentation: There are many companies offering comparable goods and services in the Diabetes Care Devices & Drugs market, which is frequently fragmented. It might be challenging to stand out from the competition and increase market share in such a crowded field.
Customer Expectations: Meeting changing customer expectations for product quality, service, and experience is a problem. Companies must continuously innovate and adapt to changing consumer tastes in order to keep and attract customers.
Market Competitive Landscape
The French Insulin Drugs and Delivery Devices Market is consolidated, with a few major and generic competitors. Mergers and acquisitions among the businesses have recently helped the companies increase their market position. Eli Lilly and Boehringer Ingelheim have collaborated to develop and commercialise Basaglar (Insulin Glargine). Furthermore, newer players have helped corporations increase their market position; for example, Novo Nordisk worked with Ypsomed to create better insulin therapy solutions.
Scope of the Report:
| Report Metric | Details |
| Market size available for years | 2020-2033 |
| Base year considered | 2023 |
| Forecast period | 2024-2033 |
| Segments covered | By Drug, By Device
|
| Regions covered | Eastern, Western, Northern, Southern
|
| Companies Covered | Novo Nordisk, Sanofi, Eli Lilly, Biocon, Medtronic, Ypsomed, Becton Dickinson.
|
COVID-19 Impact on France Diabetes Drugs and Devices Market
Diabetes mellitus is one of the most significant risk factors for developing a severe COVID-19 infection. This risk is thought to be influenced by several variables commonly found in diabetes mellitus, including advanced age, a proinflammatory and hypercoagulable condition, hyperglycemia, and underlying comorbidities (hypertension, cardiovascular disease, chronic kidney disease, and obesity). Diabetes was rapidly identified as a risk factor for poor outcomes during the COVID-19 pandemic. That is why managing or postponing the onset of type 2 diabetes has become more crucial than ever. Several studies have found that chronic disorders such as diabetes are associated with poor outcomes in COVID-19 individuals.
Key Target Audience:
- Clinicians (Endocrinologists, Diabetologists, General Practitioners)
- Diabetes Patients and Caregivers
- Government Health Agencies and Regulators
- Hospitals and Healthcare Facilities
- Insurance Providers (Health Insurance Companies)
- Medical Device Manufacturers
- Pharmaceutical Companies
- Pharmacies and Retailers
- Research Institutions and Academia
- Support Organizations (Diabetes Associations, Patient Advocacy Groups)
Our in-depth analysis of the France Diabetes Drugs and Devices Market includes the following segments:
|
By Drug:
|
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
|
|
By Device:
|
Insulin Pumps
Insulin Pens
Insulin Syringes
Insulin Jet Injectors
|
Key Topics Covered in the Report:
- France Diabetes Drugs and Devices Market Size (FY’2024-FY’2033)
- Overview of France Diabetes Drugs and Devices Market
- Segmentation of France Diabetes Drugs and Devices Market By Drug (Basal or Long-acting Insulins, Bolus or Fast-acting Insulins, Traditional Human Insulins, Combination Insulins, Biosimilar Insulin)
- Segmentation of France Diabetes Drugs and Devices Market By Device (Insulin Pumps, Insulin Pens, Insulin Syringes, Insulin Jet Injectors)
- Statistical Snap of France Diabetes Drugs and Devices Market
- Expansion Analysis of France Diabetes Drugs and Devices Market
- Problems and Obstacles in France Diabetes Drugs and Devices Market
- Competitive Landscape in the France Diabetes Drugs and Devices Market
- Impact of COVID-19 and Demonetization on France Diabetes Drugs and Devices Market
- Details on Current Investment in France Diabetes Drugs and Devices Market
- Competitive Analysis of France Diabetes Drugs and Devices Market
- Prominent Players in the France Diabetes Drugs and Devices Market
- SWOT Analysis of France Diabetes Drugs and Devices Market
- France Diabetes Drugs and Devices Market Future Outlook and Projections (FY’2024-FY’2033)
- Recommendations from Analyst
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
2. Research Methodology
2.1. Research data source
2.1.1. Secondary Data
2.1.2. Primary Data
2.1.3. SPER’s internal database
2.1.4. Premium insight from KOL’s
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.1.4. Challenges
4.2. COVID-19 Impacts of the France Diabetes Drugs and Devices Market
5. Market variable and outlook
5.1. SWOT Analysis
5.1.1. Strengths
5.1.2. Weaknesses
5.1.3. Opportunities
5.1.4. Threats
5.2. PESTEL Analysis
5.2.1. Political Landscape
5.2.2. Economic Landscape
5.2.3. Social Landscape
5.2.4. Technological Landscape
5.2.5. Environmental Landscape
5.2.6. Legal Landscape
5.3. PORTER’s Five Forces
5.3.1. Bargaining power of suppliers
5.3.2. Bargaining power of buyers
5.3.3. Threat of Substitute
5.3.4. Threat of new entrant
5.3.5. Competitive rivalry
5.4. Heat Map Analysis
6. Competitive Landscape
6.1. France Diabetes Drugs and Devices Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in France Diabetes Drugs and Devices Market
7. France Diabetes Drugs and Devices Market, By Drug (USD Million) 2020-2033
7.1. France Diabetes Drugs and Devices Market Size, Share and Forecast, By Drug, 2020-2026
7.2. France Diabetes Drugs and Devices Market Size, Share and Forecast, By Drug, 2027-2033
7.3. Basal or Long-acting Insulins
7.3.1. Lantus (Insulin Glargine)
7.3.2. Levemir (Insulin Detemir)
7.3.3. Toujeo (Insulin Glargine)
7.3.4. Tresiba (Insulin Degludec)
7.3.5. Basaglar (Insulin Glargine)
7.4. Bolus or Fast-acting Insulins
7.4.1. NovoRapid/Novolog (Insulin aspart)
7.4.2. Humalog (Insulin lispro)
7.4.3. Apidra (Insulin glulisine)
7.4.4. FIASP (Insulin aspart)
7.4.5. Admelog (Insulin lispro Sanofi)
7.5. Traditional Human Insulins
7.5.1. Novolin/Mixtard/Actrapid/Insulatard
7.5.2. Humulin
7.5.3. Insuman
7.6. Combination Insulins
7.6.1. NovoMix (Biphasic Insulin aspart)
7.6.2. Ryzodeg (Insulin degludec and Insulin aspart)
7.6.3. Xultophy (Insulin degludec and Liraglutide)
7.6.4. Soliqua/Suliqua (Insulin glargine and Lixisenatide)
7.7. Biosimilar Insulins
7.7.1. Insulin Glargine Biosimilars
7.7.2. Human Insulin Biosimilars
8. France Diabetes Drugs and Devices Market, By Device (USD Million) 2020-2033
8.1. France Diabetes Drugs and Devices Market Size, Share and Forecast, By Device, 2020-2026
8.2. France Diabetes Drugs and Devices Market Size, Share and Forecast, By Device, 2027-2033
8.3. Insulin Pumps
8.3.1. Insulin Pump Devices
8.3.2. Insulin Pump Reservoirs
8.3.3. Insulin Infusion sets
8.4. Insulin Pens
8.4.1. Cartridges in reusable pens
8.4.2. Disposable insulin pens
8.5. Insulin Syringes
8.6. Insulin Jet Injectors
9. France Diabetes Drugs and Devices Market Forecast, 2020-2033 (USD Million)
9.1. France Diabetes Drugs and Devices Market Size and Market Share
10. France Diabetes Drugs and Devices Market, By Region, 2020-2033 (USD Million)
10.1. France Diabetes Drugs and Devices Market Size and Market Share By Region (2020-2026)
10.2. France Diabetes Drugs and Devices Market Size and Market Share By Region (2027-2033)
10.3. Eastern
10.4. Western
10.5. Northern
10.6. Southern
11. Company Profile
11.1. Novo Nordisk
11.1.1. Company details
11.1.2. Financial outlook
11.1.3. Product summary
11.1.4. Recent developments
11.2. Sanofi
11.2.1. Company details
11.2.2. Financial outlook
11.2.3. Product summary
11.2.4. Recent developments
11.3. Eli Lilly
11.3.1. Company details
11.3.2. Financial outlook
11.3.3. Product summary
11.3.4. Recent developments
11.4. Biocon
11.4.1. Company details
11.4.2. Financial outlook
11.4.3. Product summary
11.4.4. Recent developments
11.5. Medtronic
11.5.1. Company details
11.5.2. Financial outlook
11.5.3. Product summary
11.5.4. Recent developments
11.6. Ypsomed
11.6.1. Company details
11.6.2. Financial outlook
11.6.3. Product summary
11.6.4. Recent developments
11.7. Becton Dickinson
11.7.1. Company details
11.7.2. Financial outlook
11.7.3. Product summary
11.7.4. Recent developments
11.8. Others
12. Conclusion
13. Reference Links
14. List of Abbreviations
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
